The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

Autor: Matoya, Sho1 (AUTHOR), Suzuki, Takanori2 (AUTHOR), Matsuura, Kentaro2 (AUTHOR) matsuura@med.nagoya-cu.ac.jp, Suzuki, Yuta3 (AUTHOR), Okumura, Fumihiro3 (AUTHOR), Nagura, Yoshihito4 (AUTHOR), Sobue, Satoshi4 (AUTHOR), Kuroyanagi, Keita5 (AUTHOR), Kusakabe, Atsunori5 (AUTHOR), Koguchi, Hiroki6 (AUTHOR), Hasegawa, Izumi6 (AUTHOR), Miyaki, Tomokatsu1 (AUTHOR), Tanaka, Yoshito7 (AUTHOR), Kondo, Hiromu7 (AUTHOR), Kimura, Yoshihide8 (AUTHOR), Ozasa, Atsushi9 (AUTHOR), Kawamura, Hayato2 (AUTHOR), Kuno, Kayoko2 (AUTHOR), Fujiwara, Kei2 (AUTHOR), Nojiri, Shunsuke2 (AUTHOR)
Zdroj: Hepatology Research. Jun2023, Vol. 53 Issue 6, p511-521. 11p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje